indazoles has been researched along with decitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bugide, S; Green, MR; Gupta, R; Wajapeyee, N | 1 |
2 other study(ies) available for indazoles and decitabine
| Article | Year |
|---|---|
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Topics: Animals; Benzopyrans; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Chemokine CXCL10; Chemokines; Decitabine; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Indazoles; Indoles; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Phenols; Pyridones; Sulfones; Triazoles | 2021 |